Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Preferred Stock Liabilities (2024)

Maze Therapeutics has reported Preferred Stock Liabilities over the past 1 years, most recently at $508.1 million for Q4 2024.

  • Quarterly Preferred Stock Liabilities changed N/A to $508.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $508.1 million through Dec 2024, changed N/A year-over-year, with the annual reading at $508.1 million for FY2024, N/A changed from the prior year.
  • Preferred Stock Liabilities was $508.1 million for Q4 2024 at Maze Therapeutics, up from $383.9 million in the prior quarter.
  • Over five years, Preferred Stock Liabilities peaked at $508.1 million in Q4 2024 and troughed at $383.9 million in Q1 2024.